Tag Archive for: CTA

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

/in

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study Boston, Massachusetts and Lausanne, Switzerland, 10 June 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a […]

Read more

Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer

/in

Revolutionary ‘off-the-shelf’ cancer vaccine designed to prevent the recurrence of oesophageal cancer ITOP1 to enter first-in-human Phase I/IIa clinical development in the VISTA study in H1 2025 Multicentre study to be conducted at four university cancer centres, aiming to raise the standard of care by reducing the recurrence of metastases and cancer-related deaths Oxford, UK […]

Read more

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata

/in

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications  ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata Health Authorities in Canada and the United States provided swift CTA & IND approval allowing for efficient dosing of the first patients Boston, Massachusetts and […]

Read more

Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510

/in

Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders Clinical Trial will investigate the safety, tolerability and pharmacokinetics of Synendos’ first-in-class ECS modulator BASEL, Switzerland – 18 January 2024 – Synendos Therapeutics AG (Synendos), a world leader in innovative Endocannabinoid System […]

Read more